Extended spectrum beta-Laktamase (ESBL)-vermittelte Antibiotikaresistenz bei gramnegativen Erregern: Was ist in der Intensivmedizin zu beachten?

Zusammenfassung

Bei der Therapie von Infektionen, die durch gramnegative Erreger verursacht werden, spielen 3. Generations-Cephalosporine eine wichtige Rolle. Extended spectrum beta-Lactamasen (ESBL) sind in der Lage, diese zu inaktivieren. Da die Zahl der ESBL-produzierenden Erreger weltweit stetig zunimmt, ist es wichtig, das Auftreten von ESBL-Bildnern rechtzeitig zu erkennen, um geeignete Maßnahmen zur Prävention und Therapie ergreifen zu können.

Abstract

Third-generation cephalosporins have an important part in the therapy of infections due to gram-negative bacteria. Extended spectrum beta-lactamases (ESBL) are able to hydrolize these antibiotics. As the number of ESBL-producing bacteria is increasing worldwide, detection of ESBL-producers is important for the both of prevention and therapy.

Schlüsselwörter

Antibiotika - Resistenz - ESBL - Prävention

Key words

Antibiotic - resistance - ESBL - prevention

Literatur

• 1 Knothe H, Shah P, Kremery V. et al . Transferable resistance to cefotaxime, cefoxitin, cefamandol and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.  Infection. 1983;  11 315-317
• 2 Lucet J C, Decre D, Fichelle A. et al . Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriacae in a university hospital.  CID. 1999;  29 1411-1418
• 3 Paterson D L, Singh N, Rihs J D. et al . Control of an outbreak of infection due to extended-spectrum β-lactamase-producing Escherichia coli in a liver transplantation unit.  CID. 2001;  33 126-128
• 4 Paterson D L. Extended-spectrum β-lactamases: the European experience.  Curr Opin Infect Dis. 2001;  14 697-701
• 5 Paterson D L. Recommendation for the treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs).  Clin Microbiol Infect. 2000;  6 460-463
• 6 Lautenbach E, Storm B L, Bilker W B. et al . Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.  CID. 2001;  33 1288-1294
• 7 Kim B H, Woo J H, Kim M N. et al . Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteriaemia.  J Hosp Infect. 2002;  52 99-106
• 8 Du B, Long Y, Liu H. et al . Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.  Intensive Care Med. 2002;  28 1718-1723
• 9 Rice L B. Successful interventions for gram-negative resistance to extended-spectrum β-lactam antibiotics.  Pharmacotherapy. 1999;  19 120S-128S
• 10 Pena C, Pujol M, Ardanuy C. et al . Epidemiology and successful control of a large outbreak due to K. pneumoniae producing extended-spectrum β-lactamases. Antimicrob.  Agents Chemother. 1998;  42 53-58
• 11 Babini G S, Livermore D M. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in southern and western europe in 1997 - 1998.  J Antimicrob Chemother. 2000;  45 183-189
• 12 Hanberger H, Garcia-Rodriguez J A, Gobernado M. et al . Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU study groups.  JAMA. 1999;  281 67-71
• 13 Perilli M, Dell'Amicod E, Segatore B. et al . Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey.  J Clin Microbiol. 2002;  40 611-614
• 14 Kresken M, Hafner D, Schmitz F J, Wichelhaus T A. (für die Studiengruppe) .Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfung und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2001. Antiinfectives Intelligence, Bonn 2003
• 15 Bradford P A. Extended-spectrum β-lactamases in the 21^st century: Characterization, epidemiology and detection of this important resistance threat.  Clin Microbiol Rev. 2001;  14 933-951
• 16 Meyer E, Jonas D, Schwab F. et al .Design of a surveillance system of antibiotic use and bacterial resistance in german intensive care units (SARI). Infection, accepted for publication. 
• 17 Witte W, Klare I. Enterobakterien verstärkt resistent durch Breitspektrum-β-Laktamasen (ESBL).  Epi Bull. 2002;  8 63-64
• 18 Smith M E, Hanson N D, Herrera V L. et al . Plasmid-mediated, carbapenem-hydrolising beta-lactamase KPC-2, in Klebsiella pneumoniae isolates.  J Antimicrob Chemother. 2003;  51 711-714
• 19 Hospital Infection Control Advisory Committee . Guidelines for isolation precautions in hospitals.  Am J Inf Control. 1996;  24 24-52
• 20 Pena C, Pujol M, Ardanuy C. et al . Epidemiology and successful control of a large outbreak due to K. pneumoniae producing extended-spectrum β-lactamases. Antimicrob.  Agents Chemother. 1998;  42 53-58
• 21 Patterson J E. Antibiotic utilization - is there an effect on antimicrobial resistance?.  Chest,. 2001;  119 S 426-S 430
• 22 Paterson D L, Rice L B. Empirical antibiotic choice for the seriously ill patient: Are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive?.  CID. 2003;  36 1006-1012
• 23 Thomson K S. Controversies about extended-spectrum and AmpC-beta-lactamases.  Emerg. Infect. Dis.. 2001;  7 333-336. Anonym.